SK Biopharm announced on the 8th that it recorded consolidated sales of KRW 133.995 billion and an operating profit of KRW 26.046 billion in the second quarter. Sales increased by 74.0% compared to the same period last year, and the company succeeded in turning operating profit positive.
The company stated, "Core sales and other revenues increased evenly," and especially explained, "The quarterly sales of Xcopri (the U.S. product name for Cenobamate), an epilepsy treatment, in the U.S. exceeded KRW 100 billion." In the second quarter, Xcopri's U.S. sales recorded KRW 105.2 billion. Regarding operating profit, the company evaluated, "The second quarter U.S. sales of Xcopri alone exceeded the quarterly selling and administrative expenses of KRW 99.2 billion," and "The increase in operating profit was driven by the growth of Xcopri's U.S. sales."
Cenobamate, SK Biopharm's core product, continues to increase the number of prescriptions and sales in the U.S. As of June, the 50th month since its launch, the total prescriptions (TRx) of Xcopri reached approximately 28,000 cases, which is about 2.2 times the average for competing new drugs at the same launch month. Cenobamate is also undergoing clinical trials to expand indications to generalized seizures, conduct Phase 3 clinical trials in Asia, and extend the eligible age group for administration to children and adolescents. The company plans to complete these soon and submit a New Drug Application (NDA) or supplemental New Drug Application (sNDA) by 2025.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
